Principal Securities, Inc. Xenon Pharmaceuticals Inc. Transaction History
Principal Securities, Inc.
- $5.32 Trillion
- Q2 2025
A detailed history of Principal Securities, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Principal Securities, Inc. holds 68 shares of XENE stock, worth $2,695. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68
Previous 58
17.24%
Holding current value
$2,695
Previous $2.27 Million
6.42%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XENE
# of Institutions
221Shares Held
72.7MCall Options Held
336KPut Options Held
309K-
Avoro Capital Advisors LLC New York, NY5.4MShares$214 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$172 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$143 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$142 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$126 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.47B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...